Market Overview
The Global Mesenchymal Stem Cells Market is expected to reach at a Significant CAGR during the forecast period 2024-2031.
Mesenchymal Stem Cells (MSCs) are multipotent stem cells found primarily in bone marrow, but also in other tissues like adipose tissue, umbilical cord, placenta and others. They are characterized by their ability to self-renew and differentiate into a variety of cell types, particularly those that make up connective tissues. These cell types include osteoblasts (bone cells), chondrocytes (cartilage cells) and adipocytes (fat cells), as well as stromal cells that provide support for blood-forming hematopoietic cells.
The market demand for mesenchymal stem cells is driven by their wide range of applications in regenerative medicine, tissue engineering, immune modulation and emerging therapies for complex diseases. For instance, according to the National Institute of Health, mesenchymal stem cells therapy is a hot topic based on its current translational application and mesenchymal stem cells have recently been listed as promising drugs for the treatment of COVID-19, thus demonstrating their important role in the treatment of inflammatory and immune diseases. Some mesenchymal stem cells have been shown to be safe and effective for clinical use.
Market Summary
| Metrics | Details |
| CAGR | Prominent Growth |
| Market Size Available for Years | 2022-2031 |
| Estimation Forecast Period | 2024-2031 |
| Revenue Units | Value (US$ Bn) |
| Segments Covered | Type |
| Source | |
| Indication | |
| Application | |
| End-User | |
| Regions Covered | North America, Europe, Asia-Pacific, South America and Middle East & Africa |
For more details on this report - Request for Sample
Market Dynamics: Drivers & Restraints
Rising prevalence of chronic diseases and degenerative conditions
The rising prevalence of chronic diseases and degenerative conditions is significantly driving the mesenchymal stem cells market and is expected to drive the market over the forecast period. This trend is due to the regenerative, anti-inflammatory and immunomodulatory properties of mesenchymal stem cells, which make them a promising therapy for a variety of chronic and degenerative health issues that traditional treatments often fail to address effectively.
For instance, Osteoarthritis is one of the most prevalent degenerative joint diseases, according to the Institute of Health Metrics and Evaluation, 595 million people were affected with osteoarthritis in 2020, globally. As populations age, the global incidence of osteoarthritis is projected to increase significantly. Mesenchymal stem cells can regenerate damaged cartilage and reduce joint inflammation, offering a treatment that not only manages pain but may also slow disease progression.
Cardiovascular diseases are the leading cause of death worldwide, according to the NIH, cardiovascular diseases account for approximately one-third of all global deaths, with 20.5 million deaths recorded in 2021. Mesenchymal stem cells have shown potential in repairing damaged heart tissue after a heart attack by promoting new blood vessel formation and reducing scar tissue. mesenchymal stem cell-based therapies for cardiac repair are in high demand as traditional treatments do not restore lost heart muscle function.
According to the World Health Organization (WHO), Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide, causing 3.5 million deaths in 2021, approximately 5% of all global deaths. Nearly 90% of COPD deaths in those under 70 years of age occur in low- and middle-income countries (LMIC). COPD treatment options are limited to managing symptoms. Mesenchymal stem cells offer potential benefits by reducing lung inflammation and promoting the repair of damaged tissue, making them a sought-after therapy in COPD management.
High cost associated with mesenchymal stem cell therapy
The high cost associated with mesenchymal stem cell therapy is a significant barrier that hampers the growth of the mesenchymal stem cells market. Despite promising applications, mesenchymal stem cell therapies remain largely inaccessible to a broad range of patients due to their expense, limiting adoption rates and slowing market expansion.
For instance, according to the Stemaid Institute, mesenchymal stem cell therapy treatment can range from $20,000 to $100,000 for whole-body treatment. Additionally, DVC Stem's IRB-approved mesenchymal stem cell protocol is currently priced at $25,000. According to the Frontiers case analysis for allogeneic mesenchymal stem cells, one administration of allogeneic mesenchymal stem cells had an expected total cost of $13,536.
Market Segment Analysis
The global mesenchymal stem cells market is segmented based on type, source, indication, application, end-user and region.
Indication:
The bone and cartilage diseases segment is expected to dominate the global mesenchymal stem cells market share
The bone and cartilage diseases segment holds a major portion of the mesenchymal stem cells market share and is expected to continue to hold a significant portion of the market share over the forecast period. Mesenchymal stem cells are especially effective in treating conditions like osteoarthritis, bone fractures and cartilage damage due to their unique ability to differentiate into bone (osteocytes) and cartilage (chondrocytes) cells, which makes them valuable in regenerative medicine for musculoskeletal disorders.
For instance, according to the World Health Organization, approximately 1.71 billion people have musculoskeletal conditions worldwide. Mesenchymal stem cells have a strong capability to differentiate into bone, cartilage and connective tissue cells, making them a targeted therapy for degenerative bone and cartilage diseases.
Their regenerative properties allow mesenchymal stem cells to repair and rebuild damaged tissues, which is critical in diseases like osteoarthritis (according to the Institute of Health Metrics and Evaluation, 595 million people were affected with osteoarthritis in 2020) and osteoporosis (according to the International Osteoporosis Foundation, osteoporosis is estimated to affect 200 million women, worldwide), where traditional treatments cannot fully restore damaged tissues.
The autoimmune diseases segment is the fastest-growing segment in the mesenchymal stem cells market
The autoimmune diseases segment is expected to be the fastest-growing segment over the forecast period. Autoimmune diseases, in which the body's immune system attacks its own tissues, are becoming more common worldwide. Conditions like rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), multiple sclerosis (MS) and inflammatory bowel diseases (IBD) are on the rise, contributing to the growing demand for effective treatments including mesenchymal stem cells.
For instance, the National Institute of Health estimates that the yearly increases in the overall worldwide incidence and prevalence of autoimmune diseases are 19.1% and 12.5%, respectively. Mesenchymal stem cells have powerful immunomodulatory effects, which can suppress the overactive immune system in autoimmune diseases. They can reduce inflammation, regulate immune cell activity and promote tissue healing, which makes them particularly effective for treating autoimmune conditions.
The increasing number of trials and positive early-phase results are driving the growth of mesenchymal stem cell-based therapies for autoimmune diseases. For instance, according to the Journal of Hematology and Oncology, over 300 clinical trials of MSC therapies have been completed in patients including degenerative or autoimmune diseases.
Market Geographical Share
North America is expected to hold a significant position in the global mesenchymal stem cells market
North America region is expected to hold the largest market share over the forecast period. North America, particularly the U.S. and Canada, has some of the most advanced healthcare infrastructures in the world, including cutting-edge hospitals, specialized clinics and research institutions. This infrastructure supports the adoption of innovative therapies like mesenchymal stem cells in treating various conditions, including orthopedic, autoimmune and degenerative diseases.
The high prevalence of chronic diseases, including osteoarthritis, rheumatoid arthritis, diabetes, and cardiovascular diseases and also autoimmune diseases has created a substantial demand for mesenchymal stem cells in North America, especially in the United States.
For instance, according to the CDC, an estimated 129 million people in the US have at least 1 major chronic disease. The National Health Council indicates that autoimmune diseases affect approximately 50 million Americans. The National Institutes for Health (NIH) estimates that they collectively affect between 5% and 8% percent of the U.S. population.
Asia Pacific is growing at the fastest pace in the mesenchymal stem cells market
The Asia Pacific region is experiencing the fastest growth in the mesenchymal stem cells market. Asia Pacific countries, including China, India, Japan and South Korea, have significantly improved their healthcare infrastructures in recent years. With the rising demand for advanced medical technologies, these countries are becoming key players in the stem cell therapy market.
The region is seeing a surge in both public and private sector investment in biotechnology and regenerative medicine. For instance, according to the University of York, in China, annual investment in stem cell research presently stands somewhere between US$4 and 10 million with 300 researchers working in 30 separate institutions, these figures are projected to increase dramatically. Similarly, in India, the government has been supporting biotech initiatives, leading to a rise in clinical trials and stem cell research.
Asia Pacific has a large and growing population of people suffering from chronic diseases such as osteoarthritis, diabetes, cardiovascular diseases and neurodegenerative disorders. According to the ESCAP, in Asia Pacific, the number of older persons is projected to more than double, from 630 million in 2020 to about 1.3 billion by 2050. With an aging population in Asia Pacific, the demand for regenerative therapies, including mesenchymal stem cells is escalating.
Market Companies
The major global players in the mesenchymal stem cells market include Thermo Fisher Scientific Inc., Merck KGaA, Lonza Ltd, Bio-Techne, STEMCELL Technologies Inc., REPROCELL Inc., AcceGen, PromoCell GmbH, Celprogen Inc., Cyagen Biosciences Inc. and among others.
Emerging Players
The emerging players in the mesenchymal stem cells market include Mesoblast Ltd., Celltex Therapeutics, Beike Biotechnology, Athersys, Inc. Cynata Therapeutics and among others.
Why Purchase the Report?
- To visualize the global mesenchymal stem cells market segmentation based on type, source, indication, application, end-user and region and understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of the mesenchymal stem cells market with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping is available in excel consisting of key products of all the major players.
The global mesenchymal stem cells market report would provide approximately 78 tables, 84 figures and 187 pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
